tbuckley/cabot-search huggingface dataset:
Depression and smoking patterns among head and neck cancer patients in an inner city minority population.
Authors: Harsha Vardhan Poola, Romy Thekkekara, Venkata Sravani Udayagiri, Urjeet Patel, David Goldberg, Fred R. Rosen
Journal: Journal of Clinical Oncology (2016)

184 Background: Continued smoking among head and neck cancer patients(HNCP) is associated with poor prognosis. These patients (pts) experience highest rates of depressive symptoms of all oncology patients. Smoking and depression are among factors that influence long term quality of life in these pts. Methods: HNCP were evaluated for patterns of smoking and depression at our Hospital. Survey using a standardized questionnaire about smoking patterns and depression using PHQ9 was employed. Pts were stratified as nonsmokers, ex-smokers (quit &gt; 6 mo), recent smokers ( &lt; 6 mo), and current smokers ( &lt; 7 days). EMR was reviewed for sociodemographic variables, stage (stg), diagnosis (Dx) date, treatment(Rx) modality. The cohort was followed till 7/31/2015 to assess disease recurrence and survival. Results: 39 pts were interviewed. Mean age at Dx was 56 +/-7 yrs. 82% were men. 46% were African American, 36% Caucasians(cau) and 8% Hispanics. 74% had stg IV disease at Dx. 76.9% were recent/current smokers at Dx. At 280 days from Dx, 41% continued smoking; decrease in smoking was statistically significant (p value: .000). 52% of smokers with stg III/IV cancer quit smoking while pts with stg I/II continued to smoke. Continued smoking was higher in Cau (p = 0.038). Mild to severe depression was seen in 56% of pts. Higher rates of depression were noted among smokers (62%) with stage III/IV disease; though it was not statistically significant. Complete response to Rx was seen in 82% and recurrence in 20.5%. No difference in outcomes based on smoking patterns was noted. Conclusions: Although smoking rates at Dx were comparable to literature, our pts had higher rates of continued smoking and depression. Dx and stg appear to be important factors in smoking cessation. SSRIs have been prophylactically used to reduce rates of depression in these pts. Studies are needed to determine if they can be used with the same success in minority population. Larger studies are also needed to assess the role of smoking cessation as a strategy to prevent depression among minority population.
ZeOxaNMulti trial: a randomized, double-blinded, placebo-controlled trial of oral zeolite “Multizeo Med” (based on PMA-zeolite – a double activated zeolite clinoptilolite called also Panalite) to prevent chemotherapy-induced side effects, in particular peripheral neuropathy
Authors: M.G. Vitale, C. Barbato, F. Habetswallner, B.M. De Martino, F. Sirico, A. Crispo, G. Cartenì
Journal: Annals of Oncology (2016)
SATB1 is repressed in FoxP3+Tregs following Grass Pollen Subcutaneous and Sublingual Immunotherapy and Correlates with Clinical efficacy
Authors: Amos Froese van Dijck, Lubna Kousar, Janice Layhadi, Oleksandra Fedina, Stefano Calvosa, Guy W. Scadding, Stephen R. Durham, Mohamed H. Shamji
Journal: Journal of Allergy and Clinical Immunology (2017)
Risk of Developing Glioma among People with Asthma: A Population-based Case-control Study
Authors: Harsheen Kaur, Conor S. Ryan, Youn Ho Shin, Hee Yun Seol, Chung-Il Wi, Katherine S. King, Euijung Ryu, Daniel H. Lachance, Young J. Juhn
Journal: Journal of Allergy and Clinical Immunology (2017)
Prolongation of Progression Free Survival In Mantle Cell Lymphoma After RHCVAD: ASCT Consolidation or Rituximab Maintenance
Authors: Jennifer McQuade, Tahamtan Ahmadi, David Porter, Noelle Frey, Alison Wakoff Loren, Steven C. Goldstein, Jakub Svoboda, Edward Stadtmauer, Stephen J. Schuster, Sunita Dwivedy Nasta
Journal: Blood (2010)
Severity profile of cow milk protein allergy IgE mediated
Authors: Claudia Leiko Yonekura Anagusko, Mariele Morandin Lopes, Larissa Prando Cau, Paula Quadros Marques, Pâmella Diogo Salles, Fabio M. Castro, Jorge Kalil, Ariana Campos Yang
Journal: Journal of Allergy and Clinical Immunology (2017)
Phase II study of <sup>131</sup>I-MIBG with vincristine and 5 days of irinotecan for patients with relapsed or refractory neuroblastoma.
Authors: Steven G. DuBois, M. Shelly Allen, Melissa Bent, Joan Hilton, Fabienne Hollinger, Jesse Courtier, Randall Hawkins, Yael P. Mosse, Katherine K. Matthay
Journal: Journal of Clinical Oncology (2014)

10033 Background: 131I-metaiodobenzylguanidine (MIBG) is a targeted radiopharmaceutical active in neuroblastoma. A previous study demonstrated that MIBG (18 mCi/kg) could be combined with vincristine and irinotecan (20 mg/m2/dose for 5 days/week x 2 weeks) as a radiation sensitizer. However, 25% of courses were associated with grade 3 diarrhea. To reduce the incidence of diarrhea, the current study evaluated MIBG together with vincristine and 5 days of higher-dose irinotecan, a standard schedule in recent pediatric trials. This report describes the experience with this regimen at maximum tolerated MIBG dose of 18 mCi/kg. Methods: Patients < 30 with relapsed or refractory MIBG-avid neuroblastoma were eligible for this multicenter trial (NCT01313936). Prior MIBG therapy was allowed if > 6 months from prior MIBG and < 18 mCi/kg cumulative prior dose. Patients received cefixime on days -1 to +6, irinotecan (50 mg/m2/dose IV) on days 0-4, and vincristine (2 mg/m2) on day 0. MIBG (18 mCi/kg) was given on day 1 and peripheral blood stem cells on day 13. Up to two courses of therapy were allowed. Response was assessed at day 42 and was the primary endpoint of this phase II portion. Consenting patients provided germline DNA for UGT1A1 genotyping. Results: 26 patients received 37 courses of therapy. Myelosuppression was the most common toxicity, with 55% of patients with grade 4 thrombocytopenia and 65% of patients with grade 4 neutropenia in course 1. No patients had failure to engraft. Only 4.5% of first courses were associated with grade 3 diarrhea. Correlation of UGT1A1 genotype with toxicity is ongoing. Centrally reviewed best response after course 1 is available for 17 patients at the time of this submission. Of these, the overall response rate was 23.5% (2 CR and 2 PR). The response rate by MIBG scan was 37.5%, including 4 CR. Conclusions: MIBG at doses of 18 mCi/kg with vincristine and 5 days of irinotecan is tolerable and active. This regimen is now being compared to single-agent MIBG in a randomized phase II trial. Clinical trial information: NCT01313936.
Consolidation Anti-CD22 Fractionated Radioimmunotherapy with 90y-Epratuzumab Tetraxetan Following R-CHOP in Elderly DLBCL Patients: A Lysa Phase II Prospective Trial
Authors: Françoise Kraeber-Bodere, Amandine Pallardy, Steven Le Gouill, Hervé Maisonneuve, Thierry Lamy, Krimo Bouabdallah, Noel Milpied, Henry Jardel, Eric Deconinck, Nadine Morineau, Charles Foussard, Annie Brion, Remy Gressin, Olivier Tournilhac, Emmanuel Gyan, Anne Moreau, Christian Berthou, Francois Dreyfus, Caroline Bodet-Milin, Anne-Laure Cazeau, Etienne Garin, Jean-Philippe Vuillez, Loic Campion, Philippe Moreau, William A Wegener, David M Goldenberg, Pierre Soubeyran
Journal: Blood (2012)
Myeloid Colony-Stimulating Factors Do Not Increase the Risk of Mortality or Disease Activity Measures in Patients with Acute Myeloid Leukemia: Systematic Review and Meta-Analysis.
Authors: Ronit Gurion, Yulia Belnik-Plitman, Anat Gafter-Gvili, Mical Paul, Liat Vidal, Isaac Ben-Bassat, Ofer Shpilberg, Pia Raanani
Journal: Blood (2009)
Prophylactic use of oral dexamethasone (DEX) to alleviate fatigue during regorafenib (REG) treatment for patients with advanced colorectal cancer (aCRC).
Authors: Shota Fukuoka, Kohei Shitara, Masaaki Noguchi, Akihito Kawazoe, Yasutoshi Kuboki, Hideaki Bando, Wataru Okamoto, Takashi Kojima, Toshihiko Doi, Atsushi Ohtsu, Takayuki Yoshino
Journal: Journal of Clinical Oncology (2015)

774 Background: Regorafenib (REG) is an oral multi-kinase inhibitor which demonstrated significant overall survival (OS) benefit for patient with advanced colorectal cancer (aCRC). Fatigue is the most common toxicity in all grade associated toxicity with REG, which is one of major reasons for early dose modification. On the other hand, recent study suggested that dexamethasone (DEX) improve the cancer associated fatigue. Methods: We retrospectively analyzed the effect of prophylactic use of oral DEX on fatigue during REG treatment for patients with aCRC. Ninety-three patients who received REG in our institution between May 2013 and June 2014 were divided into two groups according to use of oral DEX (2 mg per day; by investigator’s discretion). Outcomes measured in this study were a time to dose modification, incidences of toxicities, and anti-tumor effects. Results: Prophylactic DEX was administrated in 24 patients (DEX group) with regorafenib, and 69 patients received REG alone (no DEX). There were no significant differences in baselinepatient characteristics between 2 groups including starting dose of REG (79.1% in DEX and 84.1% in no DEX started with 160 mg/day). Time to dose modification was significantly longer in DEX than in no DEX (15 vs. 9 days; p=0.009). Incidence of fatigue (grade&gt;1) was lower in DEX (25%) than no DEX (43%) by 18%, although the difference was not statistically significant (p=0.11). Fewer patients experienced decreased appetite (grade&gt;1) with DEX than no DEX (4.2 vs. 33.3%; p=0.005) as well as hand foot skin reaction (grade&gt;3; 0 vs. 27.5%, p=0.02). In contrast, the frequency of oral candidiasis, which was improved within 1 week, was higher in DEX group (14.3% and 0%; p=0.001). Disease control rate (45.8 vs. 36.2%), progression-free survival (median, 2.1 vs. 1.8 months) and OS (median, 7.6 vs. 6.0 months) were almost compatible between DEX group and no DEX. Conclusions: Although the incidence of fatigue was not significantly decreased by use of DEX, it prolonged time to dose modification of REG in our preliminary analysis. Decreased incidence of appetite loss and HFSR also suggest that concurrent DEX with REG warrants further investigation.
Leucine-rich repeat containing 8A (LRRC8A) –dependent volume-regulated anion channel activity is dispensable for T-cell development and function
Authors: Craig D. Platt, Janet Chou, Patrick Houlihan, Yousef R. Badran, Lalit Kumar, Wayne Bainter, P. Luigi Poliani, Carlos J. Perez, Sharon Y.R. Dent, David E. Clapham, Fernando Benavides, Raif S. Geha
Journal: Journal of Allergy and Clinical Immunology (2017)
Treatment of MDS with Excess Blasts by Bevacizumab Is Well Tolerated and Is Associated with a Decrease of VEGF Plasma Level.
Authors: Laurence Legros, Boranne Slama, Jean-Michel Karsenti, Norbert Vey, Shanti Natarajan-Ame, Eric Watel, Bruno Richard, Krimo Bouabdallah, Lionnel Mannone, Irit Touitou, Sebastien Huault, Jerome Durivault, Anne-Odile Hueber, Jean-Francois Michiels, Pierre Fenaux, Francois Dreyfus
Journal: Blood (2009)
A new oral dihydroxysterol (24-ethyl-cholestane- 3&amp;bgr;,5&amp;agr;,6&amp;agr;-triol) showing activity in the treatment of advanced and metastatic breast cancer
Authors: N. Habib, H.E. Daaboul, G. Hage, A. Jabbour, H. Zeitouni, N. Kassem, R. Khalifeh
Journal: Annals of Oncology (2016)
Development of a medical record-based trigger tool for identifying adverse events during cancer care.
Authors: Allison Nicole Lipitz Snyderman, David G. Pfister, Christopher Anderson, Andrew S. Epstein, Aileen Killen, Camelia S. Sima, Coral L. Atoria, Elizabeth Fortier, David Classen, Saul Weingart
Journal: Journal of Clinical Oncology (2014)

152 Background: Adverse events for patients with cancer can be harmful and costly. Our understanding of these events and their associated harm for this patient population is limited. The objective of this study was to develop a medical record based trigger tool that can be used to help detect adverse events during cancer care. Methods: The trigger tool was developed using input from a multidisciplinary group of clinicians and researchers. First, clinicians from the study team, with input from specialists, compiled lists of adverse events that may occur during the receipt of cancer-directed treatment. Then, they created symptom-based or treatment-based ‘triggers’ that might indicate that the adverse event had occurred. From this list, the study team narrowed the triggers based on feasibility, frequency, severity of the associated adverse events, and overall expected usefulness. Additional feedback was obtained from an expert panel of nine clinicians outside the study team using a modified Delphi approach. The expert panel included representatives from medical oncology, radiation oncology, surgery, nursing, anesthesiology, general medicine, and emergency medicine. Feedback was summarized and the study team narrowed the list of triggers to create the final tool. Results: The final trigger tool for use in detecting adverse events during cancer care consisted of 76 triggers representing adverse events across organ systems. For ease of use, the tool was organized by general care, vital signs, medication related, labs, orders, and consults. Conclusions: From this study, we created a trigger tool to be used to detect key adverse events in cancer care, with an emphasis on those that may be preventable or for which the harm may be able to be mitigated. This information can be used to prioritize quality improvement activities, help to develop quality measures, and set relevant benchmarks for these events for cancer patients in order to improve the safety of cancer care.
Clinical Effect of High-Dose, Donor-Derived Natural Killer Cells Infused After HLA-Haploidentical Hematopoietic Cell Transplantation
Authors: Kyoo-Hyung Lee, Inpyo Choi, Suk Ran Yoon, Dae-Young Kim, Young-Shin Lee, Soo Yeon Park, Young-Ah Kang, Mijin Jeon, Hanna Kim, Sol-Ji Jung, Jung-Hee Lee, Je-Hwan Lee
Journal: Blood (2012)
Reply: Selection Bias in Study Participants with Acute Hypercapnic Respiratory Failure
Authors: Dan Adler, Laurent Brochard
Journal: American Journal of Respiratory and Critical Care Medicine (2017)

We reexamined the efficacy of the clinically effective anticonvulsant drug phenytoin in the kindling model. We investigated the effects of varying doses of intravenous phenytoin on serum concentrations and on several indexes of stimulation-evoked kindled seizures. Intravenous phenytoin produced a dose-dependent increase in serum phenytoin concentration and powerfully suppressed both limbic and clonic motor seizures. Although focal afterdischarge threshold was elevated to some extent, the most profound effect of phenytoin was limitation of seizure propagation. Variable and low serum concentrations of intraperitoneal or oral phenytoin may explain previous findings that phenytoin is only partly effective or ineffective against kindled seizures. Together with previous results with other drugs, the excellent correlation among drugs effective against human and kindled seizures strengthens the validity of this model. We suggest that the efficacy of experimental anticonvulsant drugs be established in the kindling model before initiation of clinical trials for partial and secondarily generalized seizures.
454P Efficacy of crizotinib in NSCLC with concomitant ALK fusion and c-MET overexpression
Authors: R-L. Chen, N-N. Lou, J-J. Yang, X-C. Zhang, H-J. Chen, J. Su, Q. Zhou, H-Y. Tu, Z. Xie, W-Z. Zhong, W-B. Guo, Y-L. Wu
Journal: Annals of Oncology (2016)
A Negative D-dimer Excludes Recurrent Deep Vein Thrombosis: Results of a Multicentre Management Study.
Authors: Shannon Bates, Clive Kearon, Susan Kahn, Jim A. Julian, Mark A. Crowther, Victor Gerdes, William Geerts, Michael J. Kovacs, Lorraine Weise-Kelly, Jeffrey S. Ginsberg
Journal: Blood (2007)
DRES-15. GLIOBLASTOMA AND TUMORS OF NEURAL-CREST LINEAGE SHARE COMMON MOLECULAR FEATURES DETERMINING VULNERABILITY TO TARGETED THERAPEUTICS
Authors: Gil Speyer, Jeff Kiefer
Journal: Neuro-Oncology (2016)

The embryonic neural crest (NC) population of cells gives rise to a number of diverse cell types and tissues. The plasticity of NC cells can also lead to the development of a wide variety of tumor types. NC derived tumors often are hallmarked by ‘mesenchymal’ like features such as increased motility, invasion, and therapeutic resistance. We have applied a unique computational network based approach, EDDY, to identify pathways enriched with mechanism-based differences in drug sensitivity across a cohort of NC derived cell lines in CCLE. EDDY combines GSEA’s gene-set-assisted advantages with the robustness of assessment of differential network dependency. It interrogates gene sets (pathways) in a database to test if dependencies across genes are significantly rewired using a novel, probabilistic statistical test between conditions, in this instance, between cell lines that are sensitive and those that are non-sensitive to specific compounds. In this study we present outcomes across the cohort of NC cell lines to four compounds targeting aspects of mesenchymal-like features, such as Met inhibition and Notch signaling inhibition. The EDDY analysis reveals pathways enriched with differential dependencies between responding vs. non-responding cell lines. For example, different pathway dependencies with RAC1 signaling is shown in response to SGX-523 Met inhibitor and RAF pathway dependencies to Notch inhibitor, semagacestat. The analysis also discovers the genes that appear to play critical roles in differential dependencies, which may be therapeutic targets. The EDDY analysis across a greater variety of compounds and NC cell lines is ongoing. This initial work provides clear pathway-based insights into drug response leading to a number of testable hypotheses for targeting neural crest-derived tumors.
Effects of 6 months of abiraterone acetate (AA) on muscle and adipose mass in men with metastatic castration-resistant prostate cancer (mCRPC).
Authors: Samuel Craig Brondfield, Vivian K. Weinberg, Kathryn M. Koepfgen, Arturo Molina, Charles J. Ryan, Eric Jay Small, Andrea Lynne Harzstark
Journal: Journal of Clinical Oncology (2012)

e15137 Background: AA, an inhibitor of androgen biosynthesis, has been shown to prolong overall survival in patients with mCRPC who have previously been treated with chemotherapy. ADT has been shown to result in muscle wasting in prostate cancer patients. The effects of AA on progression of muscle and fat wasting have not been characterized. We evaluated whether 6 months of AA therapy altered total skeletal muscle mass or adipose mass. Methods: 10 sequential patients who responded to AA therapy for at least 6 months and had available computed tomography (CT) scans were retrospectively selected from the phase I-II COU-AA-002 study. CT image analysis was used to quantify change from baseline in total skeletal muscle and adipose tissue after 6 months of AA treatment. Skeletal muscle and adipose tissue cross-sectional area were calculated at the L3 level using Slice-O-Matic software V4.3. Previously published regression models were used to estimate fat-free mass, fat mass and skeletal muscle mass. Paired t-tests were performed to determine the change in measurements. Results: At baseline, 7 of 10 patients were overweight or obese (body mass index [BMI] &gt; 25 kg/m 2 ), and none were underweight. Advanced muscle wasting (sarcopenia, previously defined as the ratio of skeletal muscle cross-sectional area at L3 level to height &lt; 52.4 cm 2 /m 2 ) was present at baseline and 6 months in 9 of 10 pts. Over 6 months of AA treatment, patients lost an average of 1.9 kg ± 3.6 kg (p = 0.13). Mean changes (kg) (±standard deviation) in total skeletal muscle mass (-0.80 ± 1.71, p = 0.18) and total non-adipose mass (-1.44 ± 3.09, p = 0.17) were not significant. A significant decrease in total adipose mass (-0.61 ± 0.84, p = 0.048) was observed. Conclusions: Sarcopenia is prevalent in patients with mCRPC. AA was not related to significantly worsening sarcopenia or overall weight loss during the first 6 months of treatment; however, this may reflect a relatively short duration of therapy and/or small sample size. A significant loss of adipose tissue was observed, which is unexpected given the known effects of ADT, which increases adipose mass. Evaluation of additional AA treated patients is ongoing.
CT Perfusion as an Early Biomarker of Treatment Efficacy in Advanced Ovarian Cancer: An ACRIN and GOG Study
Authors: Chaan S. Ng, Zheng Zhang, Susanna I. Lee, Helga S. Marques, Kyle Burgers, Feng Su, Joseph Bauza, Robert S. Mannel, Joan L. Walker, Warner King Huh, Stephen C. Rubin, Paul DiSilvestro, Lainie P. Martin, John K. Chan, Michael A. Bookman, Robert L. Coleman, Ting-Yim Lee
Journal: Clinical Cancer Research (2017)

Purpose: ACRIN 6695 was a feasibility study investigating whether CT perfusion (CTP) biomarkers are associated with progression-free survival (PFS) at 6 months (PFS-6) in patients with advanced ovarian cancer who were treated with carboplatin and either dose-dense (weekly) or conventional (3-weekly) paclitaxel, with optional bevacizumab in the prospective phase III GOG-0262 trial.Experimental Design: ACRIN 6695 recruited participants with residual disease after primary cytoreductive surgery or planned interval cytoreduction following neoadjuvant therapy, to undergo CTP studies before (T0), 3 weeks (T1), and 4 weeks (T2) after chemotherapy initiation. Tumor blood flow (BF) and blood volume (BV) were derived with commercial software. Fisher exact tests assessed the associations of CTP biomarkers changes from T0 to T2 dichotomized at zero with PFS-6 and overall radiographic response rate, while Cox regression assessed the associations between CTP biomarker changes and PFS and overall survival (OS). Bonferroni correction was used to account for multiple comparisons.Results: Seventy-six of 120 enrolled patients from 19 centers were evaluable with a median age of 61 years. BV increase was significantly associated with lower chance of PFS-6 (P = 0.028), while BF achieves borderline significance (P = 0.053). In addition, BF increase was associated with shorter PFS (HR 2.9, 95% CI, 1.3-6.4, P = 0.008) and remained significant after adjusting for age, change in tumor volume, and surgery status (P = 0.007). Neither BF nor BV changes were significantly associated with treatment response rate or OS.Conclusions: Early CTP biomarkers measurement may provide early prognostic information for PFS in newly diagnosed ovarian cancer. Clin Cancer Res; 23(14); 3684-91. ©2017 AACR.
Biomarker analyses from the phase 3 PALOMA-2 trial of palbociclib (P) with letrozole (L) compared with placebo (PLB) plus L in postmenopausal women with ER + /HER2– advanced breast cancer (ABC)
Authors: R. Finn, Y. Jiang, H. Rugo, S.L. Moulder, S.-A. Im, K.A. Gelmon, V. Dieras, M. Martin, A.A. Joy, M. Toi, E. Gauthier, D.R. Lu, C.H. Bartlett, D. Slamon
Journal: Annals of Oncology (2016)
Is a Younger 10-Allele-Matched Unrelated Donor (MUD) Better Than an Older 6-Antigen-Matched Sibling Donor (MSD) for Allogeneic HSCT?.
Authors: Jayesh Mehta, L. Gordon, M. Tallman, J. Winter, S. Williams, A. Evens, D. Grinblatt, L. Kaminer, S. Singhal
Journal: Blood (2004)
Association of Endothelial Microparticles (EMP) and Endothelial Progenitors with Serum Cholesterol Levels.
Authors: Joaquin J. Jimenez, Alexander Ferreira, Hannah J. Dodson, Katherine M. Lens, Lucia M. Mauro, Wenche Jy, Arley Peter, Eduardo De Marchena, Lawrence L. Horstman, Yeon-Soong Ahn
Journal: Blood (2006)
Peripapillary and Macular Vessel Density in Patients with Glaucoma and Single-Hemifield Visual Field Defect
Authors: Adeleh Yarmohammadi, Linda M. Zangwill, Alberto Diniz-Filho, Luke J. Saunders, Min Hee Suh, Zhichao Wu, Patricia Isabel C. Manalastas, Tadamichi Akagi, Felipe A. Medeiros, Robert N. Weinreb
Journal: Ophthalmology (2017)
MLN4924, A Novel First in Class Small Molecule Inhibitor of the Nedd8 Activating Enzyme (NAE), Has Potent Activity in Preclinical Models of Acute Myeloid Leukemia.
Authors: Ronan T. Swords, Kevin R. Kelly, Peter G. Smith, James J. Gansey, Devalingam Mahalingam, Swaminathan Padmanabhan, Michael C. O'Dwyer, Steffan T. Nawrocki, Francis J. Giles, Jennifer S. Carew
Journal: Blood (2009)